Literature DB >> 2369357

Subretinal hemorrhage management by pars plana vitrectomy and internal drainage.

E C Wade1, H W Flynn, K R Olsen, M S Blumenkranz, D H Nicholson.   

Abstract

We reviewed 14 consecutive cases of subretinal hemorrhage involving the macula, in which surgery to remove the hemorrhage was performed by the authors between February 1984 and January 1989. All patients underwent pars plana vitrectomy and internal subretinal hemorrhage drainage. The causes of subretinal hemorrhages in group 1 were primary rhegmatogenous retinal detachments (three eyes), complications from scleral buckling procedures (three eyes), traumatic retinal detachments (two eyes), and sickle cell retinopathy associated with anticoagulation therapy after a pulmonary embolus (one eye). Group 2 consisted of five eyes with massive subretinal hemorrhage associated with age-related macular degeneration. In group 1, recurrent postoperative retinal detachment occurred in five eyes but reattachment was achieved in eight of the nine eyes, and final visual acuities were 20/400 or better in those eight eyes. In group 2, marked subretinal fibrosis occurred in two eyes. Although three eyes had improved visual acuities, final visual acuities were 5/200 or worse in all five eyes.

Entities:  

Mesh:

Year:  1990        PMID: 2369357     DOI: 10.1001/archopht.1990.01070090075043

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  13 in total

1.  Scanning and transmission electron microscopic findings during RPE wound healing in vivo.

Authors:  A Oganesian; E Bueno; Q Yan; C Spee; J Black; N A Rao; P F Lopez
Journal:  Int Ophthalmol       Date:  1997       Impact factor: 2.031

2.  Visual prognosis of eyes with submacular hemorrhage associated with exudative age-related macular degeneration.

Authors:  Naoko Ueda-Arakawa; Akitaka Tsujikawa; Kenji Yamashiro; Sotaro Ooto; Hiroshi Tamura; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2012-10-04       Impact factor: 2.447

3.  Vitrectomy for the treatment of submacular hemorrhages from macular degeneration: a comparison of submacular hemorrhage/membrane removal and submacular tissue plasminogen activator-assisted pneumatic displacement.

Authors:  John T Thompson; Raymond N Sjaarda
Journal:  Trans Am Ophthalmol Soc       Date:  2005

4.  In-patient management and treatment satisfaction after intravitreous plasminogen activator injection.

Authors:  Maneli Mozaffarieh; Harald Heinzl; Stefan Sacu; Andreas Wedrich
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-05       Impact factor: 3.117

5.  Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13.

Authors:  Neil M Bressler; Susan B Bressler; Ashley L Childs; Julia A Haller; Barbara S Hawkins; Hilel Lewis; Mathew W MacCumber; Marta J Marsh; Maryann Redford; Paul Sternberg; Matthew A Thomas; George A Williams
Journal:  Ophthalmology       Date:  2004-11       Impact factor: 12.079

6.  Evacuation of subretinal hemorrhage.

Authors:  A N Dellaporta
Journal:  Int Ophthalmol       Date:  1994       Impact factor: 2.031

7.  Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator.

Authors:  R P Singh; C Patel; J E Sears
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

Review 8.  Iatrogenic retinal traumas in ophthalmic surgery.

Authors:  Daniele Tognetto; Maria Teresa di Lauro; Daniela Fanni; Adelia Zagidullina; Luca Michelone; Giuseppe Ravalico
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-07-05       Impact factor: 3.117

9.  Fibrinolysis of experimental subretinal haemorrhage without removal using tissue plasminogen activator.

Authors:  L S Morse; J D Benner; L M Hjelmeland; M B Landers
Journal:  Br J Ophthalmol       Date:  1996-07       Impact factor: 4.638

10.  Submacular hemorrhage: a study amongst Indian eyes.

Authors:  Ekta Rishi; Lingam Gopal; Pukhraj Rishi; Sabyasachi Sengupta; Tarun Sharma
Journal:  Indian J Ophthalmol       Date:  2012 Nov-Dec       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.